Prothena (PRTA) Stock Overview
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PRTA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.69 |
| 52 Week High | US$16.67 |
| 52 Week Low | US$4.32 |
| Beta | -0.10 |
| 1 Month Change | -6.83% |
| 3 Month Change | 3.53% |
| 1 Year Change | -37.08% |
| 3 Year Change | -83.27% |
| 5 Year Change | -21.73% |
| Change since IPO | 34.58% |
Recent News & Updates
Recent updates
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Dec 11
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts
May 29Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place
May 27Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge
May 22Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
Apr 02
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.Prothena Corporation: Multiple Failures Make It Risky
Mar 03Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think
Feb 22Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price
Jan 24Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Dec 22Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
Nov 06Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Oct 18Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Oct 02Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
Jul 26Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Jun 19Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Jun 07New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
May 14Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Feb 23Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Feb 08Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?
Dec 20Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Nov 24Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk
Oct 27Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Aug 25Shareholder Returns
| PRTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | 2.6% | 2.6% |
| 1Y | -37.1% | 25.9% | 14.2% |
Return vs Industry: PRTA underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: PRTA underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| PRTA volatility | |
|---|---|
| PRTA Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRTA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 163 | Gene Kinney | www.prothena.com |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.
Prothena Corporation plc Fundamentals Summary
| PRTA fundamental statistics | |
|---|---|
| Market cap | US$521.61m |
| Earnings (TTM) | -US$280.46m |
| Revenue (TTM) | US$11.79m |
Is PRTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTA income statement (TTM) | |
|---|---|
| Revenue | US$11.79m |
| Cost of Revenue | US$170.44m |
| Gross Profit | -US$158.65m |
| Other Expenses | US$121.81m |
| Earnings | -US$280.46m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.21 |
| Gross Margin | -1,346.11% |
| Net Profit Margin | -2,379.59% |
| Debt/Equity Ratio | 0% |
How did PRTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 21:27 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prothena Corporation plc is covered by 23 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |